Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GE Healthcare partnering on regenerative tissue manufacturing

By Chris Newmarker | December 9, 2019

GE Healthcare Advanced Solutions Life SciencesGE Healthcare Life Sciences said today that it has entered into a strategic R&D and distribution partnership with Advanced Solutions Life Sciences — with a goal of personalized tissue regeneration.

The partnership with Advanced Solutions Life Sciences is the latest in a string of investments and partnerships that GE Healthcare (NYSE:GE) has been making to further a wide array of medtech innovation — from 3D printing to robot-assisted surgery to artificial intelligence to digital health.

The integration of GE’s IN Cell Analyzer with Advanced Solutions Life Sciences’ BioAssemblyBot systems will involve embedding cellular-level assessments into the 3D-bioprinting workflow used to create human tissue models, according to the companies. The deal is about designing, building and imaging living, vascularized 3D tissues in a single process, according to the companies.

Get the full story on our sister site MassDevice. 


Filed Under: Uncategorized
Tagged With: Advanced Solutions Life Sciences, GE Healthcare
 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Related Articles Read More >

Why Regeneron’s Lynozyfic FDA approval validates its extreme R&D thesis
Parallel Bio’s $21M in Series A will drive aim to trim $2B and 9 years from drug development timelines
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE